Yet even if one does take that jaundiced view, the good news is that H-P has at least gained some critical breathing room despite share prices sinking to 10-year lows.
No deliberations over a Hurd or an Apotheker can mean much when the board is content to let a company like H-P lurch from pillar to post in hopes of quick revenue injections to stave off inevitable market share erosions.